Family history of Alzheimer’s disease, but not APOE, is associated with brain volume in cognitively healthy older adults
Background Dementias, particularly Alzheimer's disease (AD), represent a global public health concern. Although its exact cause remains unknown, neuroanatomical and cognitive changes are crucial. Objective Finding biomarkers helping the early diagnosis of AD is crucial for developing early inte...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Autónoma de Madrid |
| Repositorio: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.uam.es:10486/720598 |
| Acceso en línea: | http://hdl.handle.net/10486/720598 https://dx.doi.org/10.3233/ADR-240105 |
| Access Level: | acceso abierto |
| Palabra clave: | apolipoprotein E4 early diagnosis family history of Alzheimer’s disease hippocampus magnetic resonance imaging Psicología |
| Sumario: | Background Dementias, particularly Alzheimer's disease (AD), represent a global public health concern. Although its exact cause remains unknown, neuroanatomical and cognitive changes are crucial. Objective Finding biomarkers helping the early diagnosis of AD is crucial for developing early interventions. Methods In a sample of 402 cognitively healthy adults some of them with risk factors (family history of AD and APOE ε4 carriers), we examined the relationship between APOE ε4 genotype and other aspects of family history of AD with cognitive variables and brain volumetrics using magnetic resonance imaging (MRI). Results Key findings suggest that family history of AD may be associated with specific neuroanatomical markers, such as left hippocampal size and white matter integrity. However, no links were observed with cognitive performance, and furthermore additional analyses on the APOE genotype showed no significant differences in any neuroanatomical aspect. Conclusions This study reveals the importance of monitoring with MRI subjects with family history of AD, to assess early volumetric changes and use this information to stratify participants in future clinical trials |
|---|